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Selectins (endothelial (E), platelet (P) and leucocytes (L)) are a class of cell adhesion molecules, stimulated in response to
inflammation. Pre-eclampsia is characterized by inflammation, and angiotensin II is pro-inflammatory.
We hypothesised that circulating maternal and fetal concentrations and placental expression of selectins would be increased in
women with pre-eclampsia and would be associated with the angiotensin receptors (AT1R and AT2R).
Maternal and fetal blood and placental tissue was collected at delivery from White European normotensive controls (n=17) and
women with pre-eclampsia (n=17). Soluble (s) E-, P- and L-selectin protein concentrations were measured by ELISA and placental
protein expression was examined by immunohistochemistry.
Maternal sE-selectin concentrations were increased in pre-eclampsia (P<0.001); conversely fetal sE- and sP-selectin levels were
lower in pre-eclampsia (P<0.05 for both). Staining was mainly localised to the syncytiotrophoblast for all selectins. E-selectin
expression was increased, while P-selectin was decreased in placental from pre-eclampsia (P<0.05 for both); no differences were
observed for L-selectin expression. Both E- and L-selectin were positively correlated (P<0.008; P<0.02) with AT2R placental
expression, whilst P-selectin was negatively associated with AT1R (P<0.005), all only in the pre-eclampsia group.
This novel study reports maternal, fetal and placental expression of selectins in pre-eclampsia. The increased E-selectins reflect the
endothelial dysfunction, characteristic of pre-eclampsia. In contrast, the reduced P-selectins and the positive association of
placental AT2Rs with both E-and L-selectin in pre-eclampsia could be a protective mechanism to limit the endothelial dysfunction.
  
 Contribution to the field
Pre-eclampsia is a pregnancy-specific syndrome characterised by de novo high blood pressure and protein in the urine after 20
weeks gestation and is one of the leading causes of maternal and fetal mortality and morbidity worldwide. Delivery of the infant
is the only treatment, However, consequences of this pregnancy-induced disease lasts for the entire life. Selectins (endothelial (E),
platelet (P) and lymphocytes (L)) are a class of cell adhesion molecules that are stimulated in response to inflammation. They have
never been quantified in maternal and fetal circulation nor in placenta in healthy pregnancy and in pre-eclampsia. We are the first
to report maternal, fetal and placental expression of all 3 selectins in pre-eclampsia with the increased levels E-selectin levels in
pre-eclampsia reflecting the endothelial dysfunction, associated with the syndrome of pre-eclampsia. The additional positive
correlation with placental angiotensin 2 receptor expression leading to vasoconstriction in the pre-eclamptic samples supports the
hypothesis of a protective mechanism. These novel data reflect maternal and placental endothelial dysfunction in pre-eclampsia,
which may be protected in the fetus. Thus, our study provides a functional role of these selectins in the pathophysiology of
pre-eclampsia. Targeting these molecules could be of benefit for the pregnancy outcome.
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Abstract  50 
 51 
Selectins (endothelial (E), platelet (P) and leucocytes (L)) are a class of cell adhesion 52 
molecules, stimulated in response to inflammation. Pre-eclampsia is characterized by 53 
inflammation, and angiotensin II is pro-inflammatory.  54 
We hypothesised that circulating maternal and fetal concentrations and placental expression 55 
of selectins would be increased in women with pre-eclampsia and would be associated with 56 
the angiotensin receptors (AT1R and AT2R).  57 
Maternal and fetal blood and placental tissue was collected at delivery from White European 58 
normotensive controls (n=17) and women with pre-eclampsia (n=17). Soluble (s) E-, P- and 59 
L-selectin protein concentrations were measured by ELISA and placental protein expression 60 
was examined by immunohistochemistry.  61 
Maternal sE-selectin concentrations were increased in pre-eclampsia (P<0.001); conversely 62 
fetal sE- and sP-selectin levels were lower in pre-eclampsia (P<0.05 for both). Staining was 63 
mainly localised to the syncytiotrophoblast for all selectins. E-selectin expression was 64 
increased, while P-selectin was decreased in placental from pre-eclampsia (P<0.05 for both); 65 
no differences were observed for L-selectin expression. Both E- and L-selectin were 66 
positively correlated (P<0.008; P<0.02) with AT2R placental expression, whilst P-selectin 67 
was negatively associated with AT1R (P<0.005), all only in the pre-eclampsia group.  68 
This novel study reports maternal, fetal and placental expression of selectins in pre-69 
eclampsia. The increased E-selectins reflect the endothelial dysfunction, characteristic of pre-70 
eclampsia. In contrast, the reduced P-selectins and the positive association of placental 71 
AT2Rs with both E-and L-selectin in pre-eclampsia could be a protective mechanism to limit 72 
the endothelial dysfunction.  73 
Keywords: Selectins; Angiotensin Receptors; Endothelial Dysfunction; Pre-eclampsia; 74 
Inflammation. 75 
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Introduction 97 
 98 
Pre-eclampsia is a pregnancy-specific syndrome characterised by de novo hypertension and 99 
proteinuria after 20 weeks gestation (1). It affects between 2-8% of all pregnancies and is a 100 
major cause of both maternal and perinatal morbidity and mortality worldwide (2, 3). The 101 
consequences of pre-eclampsia are not restricted to pregnancy, with both mothers and their 102 
offspring being at increased in risk of cardiovascular, metabolic and renal disease in later life 103 
(4, 5).  The aetiology of pre-eclampsia remains unknown, but endothelial dysfunction due to 104 
abnormal placentation, oxidative stress, extensive leucocyte activation and inappropriate 105 
activation of the renin-angiotensin system (RAS) appear to be key contributors (6-10).  The 106 
endothelium is the main regulator of vascular homeostasis. In addition to contributing to 107 
vasodilation, the intact endothelium also has anti-aggregatory, anti-inflammatory and anti-108 
proliferative properties (11).  Hypertension is associated with endothelial dysfunction, which 109 
in turn results from a dysregulation of locally-acting mediators, such as the vasodilators nitric 110 
oxide, and prostacyclin and the vasoconstrictor endothelin, and angiotensin II (Ang II)  111 
 112 
The RAS is an  important regulator of blood pressure and is one of the first hormonal systems 113 
to recognise pregnancy (10). Moreover, the RAS also plays a role in various pathological 114 
situations involving regulation of cell proliferation, inflammation, oxidative stress and 115 
angiogenesis (12, 13). We have previously demonstrated a disrupted placental RAS in pre-116 
eclampsia with the angiotensin II type 1 receptor (AT1R), activation of which results in 117 
vasoconstriction, being more highly expressed in placentae from women with pre-eclampsia 118 
(14). 119 
 120 
Selectins are type 1 transmembrane proteins and are involved in leucocyte trafficking, 121 
mediating the initial tethering and rolling interactions between blood and lymphatic organs 122 
via the endothelium (15). Selectins were so named because of their ability to selectively bind 123 
carbohydrate moieties via their ligand P-selectin glycoprotein ligand-1 (PSGL-1) (15). There 124 
are three types of selectins, endothelial E-, platelets P- and leucocyte L-selectins; CD62E, 125 
CD62P and CD62L, respectively.  All 3 selectins are composed of common extracellular 126 
domains and are distinguished from one another by their variable number of consensus 127 
repeats and very different cytoplasmic tails (16). E-selectin is normally absent from resting 128 
endothelium, but is transcriptionally induced in venules of multiple organs by inflammatory 129 
mediators, such as tumour necrosis factor (TNF) and IL-1 (17). P-selectin is constitutively 130 
synthesised in both platelets and endothelial cells and stored in Weibel-Palade bodies. They 131 
are rapidly translocated to the surface upon stimulation with inflammatory mediators, such as 132 
thrombin, histamine and platelet-activating factor (17). 133 
 134 
The shortest selectin molecule, present in leukocytes, is L-selectin, which, in the 135 
microvasculature, facilitates neutrophil rolling and migration during inflammatory responses 136 
(18). Elevated sE-selectin levels may be indicative of endothelial cell activation and damage. 137 
In addition to the conventional roles described above, the selectins play an essential role in 138 
human implantation; L-selectin and its ligands participate in the adhesion of the blastocyst to 139 
the endometrium at the maternal-fetal interface (19). Moreover, P- and E-selectins are also 140 
involved in immune recognition between maternal decidua and the embedded embryo, as 141 
well as trophoblast migration within decidual spiral arterioles (19). Reduced expression of all 142 
selectins has been reported in both decidual cells in uterine decidual stroma and in the 143 
placenta (cytotrophoblasts and syncytiotrophoblasts) of early miscarriages (6-11 weeks) 144 
compared to controls (terminations for social reasons) (20). 145 
 146 
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Concentrations of both soluble (s) E- and P-selectins have been reported to be increased in 147 
patients with chronic hypertension with the most severe endothelial dysfunction (21). 148 
Previous studies have reported elevated maternal plasma sE-selectin concentrations in women 149 
with pre-eclampsia, both at the time of delivery (22-26) and also prior to clinical diagnosis 150 
(22). However, the available data concerning both sP- and sL-selectins (22, 23, 26, 27) are 151 
conflicting.  152 
 153 
Associations between the RAS and the selectins have previously been reported: Ang II is a 154 
potent stimulus to angiogenesis, both directly and by supplying angiogenic factors by platelet 155 
aggregation (28) and inducing the expression of P-selectin on platelets, while lessening its 156 
expression in endothelial cells (29). In addition, platelets express AT1R on their surface, and 157 
AT1R antagonists reduce P-selectin expression in platelets (30) and inhibit P-selectin-158 
mediated platelet adhesion to the microvessels (31). Ang II also acts directly on naive T cells 159 
inducing upregulation of L-selectin via the AT1R (32). Finally, Ang II treatment significantly 160 
increased E-selectin mRNA expression in vascular endothelial cells collected from lung 161 
tissues in a mouse model of pulmonary metastasis (33). 162 
 163 
We hypothesised that both soluble and placental expression of selectins would be increased 164 
in women with pre-eclampsia reflecting the endothelial dysfunction and inflammation 165 
characteristic of the syndrome. These selectins would also be associated with RAS receptors, 166 
contributing to the mechanistic changes associated with pre-eclampsia. This study therefore 167 
aimed to measure both soluble and placental expression of all selectins in matched maternal, 168 
fetal and placental samples from normotensive control women and women with pre-169 
eclampsia. 170 
171 In revi
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Materials & Methods 172 
Subjects and sample collection 173 
The study population consisted of 17 normotensive control women and 17 women with pre-174 
eclampsia, collected over a period of 18 months (Table I).  Nottingham University Hospital 175 
Ethics Committee approved the investigations and written informed consent to participation 176 
was obtained from each woman. Cases were defined on admission with a clinical diagnosis of 177 
pre-eclampsia, defined as a systolic blood pressure of ≥ 140 mm Hg and diastolic pressure 178 
(Korotkoff V) of ≥ 90 mm Hg on 2 occasions after 20 weeks’ gestation in a previously 179 
normotensive women and proteinuria > 300 mg/L, 500 mg/day or 2+ on dipstick analysis of 180 
midstream urine (MSU) if 24-hour collection result was not available (1). Although samples 181 
were collected under the criteria defined originally (1), they still fit the recently updated 182 
definition (34).  For subgroup analysis, the pre-eclampsia group was further split by early- 183 
(diagnosis ≤ 34 weeks) and late- (diagnosis >34 weeks) onset pre-eclampsia (35). Medical 184 
and obstetric histories, including delivery data, were obtained for each woman. The 185 
birthweight centile for each baby was computed, correcting for gestation age, sex, maternal 186 
parity and body mass index (BMI) (36). Venous blood samples were collected before 187 
delivery and umbilical venous (fetal) blood were collected immediately after and processed 188 
as previously described (6); samples were stored in aliquots at -80 oC until analysis. In 189 
addition, placental tissue samples were collected from a standardised location midway 190 
between cord insertion and placental border and processed for immunohistochemistry as 191 
previously described (6). 192 
Soluble selectin assays 193 
Soluble (s) E-, P- and L-selectin were measured in maternal and fetal EDTA plasma using 194 
ELISAs (KA0116, KA0548 and KA0117 respectively; Abnova, Taiwan) following the 195 
manufacturers’ instructions. Plasma samples were diluted 1:100, run in duplicate and blinded 196 
to outcome group. Intra- and inter-assay variations were: sE-selectin: 5.4% and 6%; sP-197 
selectin: 5.5% and 6.1%; sL-selectin: 3.7% and 4.2%. 198 
Placental selectin protein expression/localisation 199 
Immunohistochemical analysis was performed as previously described (37), using antibodies 200 
to E-selectin (mouse monoclonal, BBA16; 5 µg/mL; R&D Systems), P-selectin (mouse 201 
monoclonal, BBA30; 10 µg/mL; R&D Systems) and L-selectin (rabbit polyclonal, 202 
GTX59778; 0.1 µg/mL; GeneTex Inc.). All slides were assessed by the same observer, 203 
blinded to pregnancy outcome. Quantification was performed as described previously (12), 204 
using the Positive Pixel Algorithm of Aperio ImageScope software; a visual check was also 205 
performed to establish localisation of staining. The AT1R and AT2R protein expression 206 
analysis was performed as previously reported (14). 207 
Statistical analysis 208 
All tests were performed using SPSS version 24. Summary data are presented as means ± 209 
standard deviation (SD) or median and interquartile range (IQR) as appropriate. The 210 
Kolmogorov-Smirnov test indicated the experimental data were not normally-distributed. The 211 
Kruskal-Wallis test followed by Mann-Whitney U-test was used for multiple group analysis; 212 
the Wilcoxon paired tests were used for maternal and fetal selectin concentrations. Potential 213 
associations between continuous data were tested using Spearman’s Rho correlation tests. 214 
The null hypothesis was rejected where P<0.05. 215 
  216 
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Results 217 
 218 
Subjects 219 
 220 
Demographics and clinical characteristics of the participants are summarised in Table I. By 221 
definition, blood pressures were significantly increased (P < 0.05) and significant proteinuria 222 
was present in the pre-eclampsia group. Birthweights were also lower in the women who 223 
suffered from pre-eclampsia. The groups were matched for maternal age, BMI, smoking 224 
status, parity and gestational age at delivery.   225 
 226 
Soluble selectin concentrations in maternal and fetal plasma 227 
 228 
Concentrations of all soluble selectins are summarised in Fig 1. Maternal sE-selectin was 229 
increased in pre-eclampsia compared to controls (P < 0.05; Fig 1A). No significant 230 
differences were observed for sP- or sL-selectins (P > 0.05 for both; Fig 1B & C). In contrast, 231 
in the fetus, both sE- and sP-selectin concentrations were lower in the pre-eclampsia group (P 232 
< 0.05 for both; Fig. 1A & B), but did not differ for sL-selectin (P > 0.05; Fig. 1C). 233 
 234 
When comparing paired maternal-fetal samples, both sE- and sP-selectin concentrations were 235 
increased in fetal compared to maternal plasma only in the normotensive group (P < 0.05 for 236 
both; Fig 1A & B); fetal plasma from women who had pre-eclampsia remaining similar to 237 
their paired maternal plasma (P > 0.05). Conversely, fetal sL-selectin concentrations were 238 
reduced compared to their paired maternal samples in both groups (P < 0.05; Fig 1C). 239 
 240 
When sub-grouped by early-/late-onset pre-eclampsia, only maternal sE-selectin 241 
concentrations were raised in plasma from early-onset (n = 6) pre-eclampsia (P = 0.003), 242 
compared to both late-onset (n = 11) pre-eclampsia (P = 0.01) and normotensive controls (P 243 
= 0.002; Figure 1D). No differences were seen for either sP- or sL-selectin concentrations 244 
(P>0.05 for both; data not shown).  245 
 246 
Ratio between maternal and fetal sE-, sP- and sL-selectin was calculated (Fig 2). 247 
Significantly increased ratios were observed for both sE- (P = 0.001) and sP- (P = 0.02) 248 
selectin in pre-eclampsia, compared to normotensive controls. No differences were observed 249 
for sL-selectin (P > 0.05).  250 
 251 
Placental selectin protein expression 252 
 253 
Placental expression of all 3 selectins was determined and localisation was mainly in the 254 
syncytiotrophoblast layer, stromal areas and some fetal vessel staining (Fig. 3). Placental E-255 
selectin expression was increased in pre-eclampsia (median [IQR], positivity; normotensive 256 
controls: 0.56 [0.51, 0.65]; pre-eclampsia: 0.71 [0.60, 0.80]; P = 0.008; Fig. 3A), whereas P-257 
selectin was reduced in pre-eclampsia (normotensive controls 0.47 [0.34, 0.59]; pre-258 
eclampsia 0.35 [0.22, 0.41]; P = 0.008; Fig. 3B). E-selectin expression levels were raised (P 259 
= 0.002), while P-selectin expression was reduced in both the early- and late-onset pre-260 
eclampsia groups, compared to normotensive control samples (P<0.05; Figs. 3D & 3E). 261 
 262 
Although no differences were observed between controls and pre-eclamptic women for L-263 
selectin (P >0.05; Fig. 3C), when sub-grouped by onset of pre-eclampsia, a significant 264 
difference again became apparent the expression being increased in early-onset pre-eclampsia 265 
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group expression compared to both normotensive controls (P = 0.008) and late-onset pre-266 
eclampsia (P = 0.002; Fig. 3F).  267 
 268 
Association of placental expression of selectins with AT1R and AT2R 269 
 270 
We compared placental expression of selectins with previously measured AT1R and AT2R 271 
placental protein expression. In the pre-eclampsia samples, but not those from normotensive 272 
women, placental expression of both E-selectin (r = 0.55; P = 0.008; Fig. 4A) and L-selectin 273 
(r = 0.61; P = 0.02; Fig. 4B) positively correlated with AT2R expression. In contrast, again 274 
only in the pre-eclampsia group, P-selectin displayed a negative association with AT1R 275 
expression (r = 0.68; P = 0.005; Fig. 4C).   276 
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Discussion 277 
 278 
This is the first study to present data on all selectins in paired maternal/fetal plasma together 279 
with their placental expression in women with and without pre-eclampsia. It helps clarify the 280 
conflicting data found previously in relation to P- and L-selectin in pregnancy and pre-281 
eclampsia. 282 
 283 
The increased maternal sE-selectin in pre-eclampsia is in accordance with previous reports 284 
(22, 23, 25, 26). We have now shown that there is also increased placental E-selectin, 285 
reflecting the overall endothelial dysfunction associated with pre-eclampsia. Furthermore, the 286 
markedly increased concentrations of maternal sE-selectin, found only in the early-onset pre-287 
eclampsia group (Figure 1D), presumably reflect the severity of the syndrome, as has been 288 
suggested by others (24). This is further supported by the finding that sE-selectin is increased 289 
prior to clinical diagnosis of pre-eclampsia (22, 38). Moreover, Chen et al., have shown that 290 
maternal sE-selectin was not associated with all cases of preterm birth, but specifically only 291 
when complicated by pre-eclampsia (39). The increased placental E-selectin expression we 292 
have shown corresponds with increased maternal sE-selectin and suggests that the placental 293 
dysfunction contributes to the endothelial damage in pre-eclampsia. Shaw et al., reported 294 
increased E-selectin mRNA expression in endothelial cell HUVECs and HEECs after 295 
incubation with maternal perfusates obtained from placentae of women with pre-eclampsia 296 
(40), which might amplify the underlying difference.  297 
 298 
The interesting finding of reduced fetal sE-selectin in pre-eclampsia could either be a 299 
protective adaptation to limit the endothelial damage to the fetus, or reflects an underlying 300 
inability to synthesise E-selectin.  Since E-selectin can be induced on fetal endothelial cells to 301 
the same extent as adult vessels by 32 weeks’ gestation (17, 41) and the gestational age of the 302 
early-onset PE group was nearer 34 weeks, this supports the view that the difference is 303 
attributable to the pre-eclampsia pathology and not an immaturity of development. sE-304 
selectin also contributes to homing in the endothelial progenitor cells and promotes tube 305 
formation in microvasculature as a repair mechanism (42). Given that there is reduced tubule 306 
formation in HUVECS isolated from pre-eclamptic pregnancies (43), this further suggests 307 
that the functional capacity of fetal endothelial cells is impaired in pre-eclampsia. 308 
 309 
Nevertheless, the positive correlation with placental AT2R expression only in the pre-310 
eclamptic samples supports the hypothesis of a protective mechanism; AT2R forms part of 311 
the ‘protective’ arm of the RAS and is strongly upregulated following tissue damage such a 312 
vascular and neuronal injury (44). AT2R confers this role through its anti-inflammatory, anti-313 
fibrotic and anti-apoptotic properties. Moreover, in lung tissues, which have many parallels 314 
with the placenta, Ang II treatment significantly increased E-selectin mRNA expression in 315 
vascular endothelial cells, further supporting the association (33). 316 
 317 
We did not identify any differences in maternal sP-selectin between groups, which is in 318 
contrast to a previous study, which reported increased levels in pre-eclampsia (23, 26). A 319 
potential explanation for this difference lies in the later gestation age at sampling in our study 320 
when compared to the previous study. The lack of differences in sP-selectins between groups 321 
could have been due to our not measuring platelet sP-selectin levels. Nevertheless, by using 322 
whole plasma, we were able to measure all 3 selectins. 323 
 324 
As with sE-selectins, the lower fetal P-selectin concentrations in the pre-eclamptic group 325 
could be a protective mechanism to limited endothelial damage to the fetus. The reduced 326 
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placental P-selectin expression in pre-eclampsia could also contribute to lower fetal sP-327 
selectin. In addition, the decreased P-selectin could also be explained by the known reduction 328 
in platelet numbers in pre-eclampsia (34). Furthermore, the inverse relationship with AT1R, 329 
suggests this is independent of AT1R expressed on platelets. Ang II can increase P-selectin 330 
expression within the vascular wall (45) and thus increase atherosclerotic plaque progression. 331 
Therefore, the reduced placental P-selectin expression in pre-eclampsia could be a feedback 332 
mechanism to limit this damage and is supported by this negative correlation with AT1R. 333 
 334 
Inspection of Fig 2a and 2b led us to suggest that the ratio between maternal and fetal sE- or 335 
sP-selectin might differ between normotensive and pre-eclamptic women, and in early and 336 
late-onset pre-eclampsia. As fig 3 shows, this is indeed the case, again emphasising a possible 337 
protective mechanism. 338 
 339 
The lack of differences observed between groups in sL-selectin in plasma may be because 340 
differences are only seen in specific cell types, for example the decreased levels in pre-341 
eclampsia reported in neutrophils, T-cells and monocytes (46). However, although not 342 
significant, there did appear to be a trend towards reduced maternal sL-selectin 343 
concentrations in the early-onset pre-eclamptic group. This is in line with previous studies 344 
where the majority of the pre-eclamptic samples measured were from early-onset pre-345 
eclampsia (23, 47). To investigate this fully, future studies will examine whether any 346 
differences are observed when leukocytes and platelets are isolated and analysed to confirm if 347 
the differences in this study are confirmed, or were masked by measuring in whole plasma. In 348 
contrast, there is increased placental expression in placentae from the early-onset pre-349 
eclampsia group, which is not reflected in parallel increases in the maternal or fetal 350 
circulation. This again suggests a possible protective mechanism, further supported by the 351 
positive association seen with placental AT2R expression in the pre-eclamptic group. It has 352 
been suggested that these lower levels result in increased leukocyte activation as seen in some 353 
chronic inflammatory states (e.g. chronic artery disease (48)). We can thus speculate that the 354 
increased placental L-selectin in early-onset pre-eclampsia could lead to increased leucocyte 355 
activation and therefore atherosis in these placentae.  356 
 357 
To conclude, this study is the first to report matched maternal, fetal and placental expression 358 
of all 3 selectins in pre-eclampsia. The increased E-selectins reflect the endothelial 359 
dysfunction, characteristic of pre-eclampsia. In contrast, the reduced P-selectins and the 360 
positive association with the placental AT2R with both E-and L-selectin in pre-eclampsia 361 
could be a protective mechanism to limit the endothelial dysfunction. Due to the roles of the 362 
selectins, this observational study further supports the importance of endothelial cells, 363 
platelets and leucocytes in the pathogenesis of pre-eclampsia.   364 
 365 
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Figure legends: 536 
 537 
Figure 1. Maternal and fetal soluble (s) A) E-selectin; B) P-selection and C) L-selectin 538 
concentrations between normotensive control (NC) and pre-eclamptic (PE) pregnancies. D) 539 
Maternal sE-selectin concentrations when sub-grouped by NC, early-onset PE (diagnosis ≤34 540 
weeks gestation; n = 6) and late-onset PE (>34 weeks gestation; n = 11). Data presented as 541 
median [IQR]; *P<0.05; ***P<0.0001. 542 
 543 
Figure 2. Maternal:fetal ratios of soluble (s) A) E-selectin; B) P-selection and C) L-selectin 544 
concentrations between normotensive control (NC) and pre-eclamptic (PE) pregnancies. Data 545 
in all box plots are presented as median [interquartile ranges]; **P<0.001. 546 
 547 
Figure 3. Localisation and quantification of placental A) E-selectin; B) P-selectin and C) L-548 
selectin in placentae from normotensive controls (NC (A1, B1 & C1); n = 17) and pre-549 
eclampsia (PE (A2, B2 & C2); n = 17). Negative controls for each selectins are shown in A3, 550 
B3 & C3 respectively. In photomicrographs, positive cells appear in brown; magnification 551 
x400. Scale bars represent 100 µm. Protein expression was localised to the 552 
syncytiotrophoblast layer (black arrows) and some fetal vessels (red arrows).  Figures D) E-553 
selectin; E) P-selectin and F) L-selectin expression in placentae, when sub-grouped by NC, 554 
early-onset PE (diagnosis ≤34 weeks gestation; n = 6) and late-onset PE (>34 weeks 555 
gestation; n = 11).  Data in all box plots are presented as median [interquartile ranges]; 556 
*P<0.05; **P<0.001.  557 
 558 
Figure 4. Scatter plots illustrating the positive relationship between A) placental E-selectin (r 559 
=0.55; P = 0.008) and B) L-selectin (r =0.61; P = 0.02) with angiotensin type 2 receptor 560 
(AT2R) and C) the negative association between placental P-selectin (r =0.68; P = 0.005) 561 
with angiotensin type 1 receptor (AT1R).  562 
 563 
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Table I. Clinical and obstetric data of subject groups* 586 
 587 
Parameter NC (n = 17) PE (n = 17) 
Age (yrs)  28.2 ± 7.2 31 ± 6.5 
Booking body mass index (Kg/m2)  26.4 ± 5.5 24.8 ± 3.5 
Smoking status  
   Non-smoker 
   Smoker 
 
9 (53) 
8 (47) 
 
11 (65) 
6 (35) 
Parity  
   Nulliparous 
  Multiparous 
 
11 (65) 
6 (35) 
 
10 (59) 
7 (41) 
Max. systolic blood pressure 
(mmHg) 
114 ± 3.8 155 ± 3.8† 
Max. diastolic blood pressure 
(mmHg) 
75 ± 2.1 97 ± 5.0† 
Proteinuria (g/L) Median [min, 
max] 
- 1.0 [0.3, 9.4] 
Gestational age at delivery (Wks)  40.0 ± 1.0 37.7 ± 1.8 
Mean birthweight (g)  3439 ± 498 2993 ± 735† 
Corrected birthweight centile  27.9 [17.5, 66.8] 35.1 [8.6, 76.3] 
Caesarean section  4 (24) 13 (76) 
Early-onset PE - 6 (35) 
 588 
*Data represented as means ± SD or median [IQR] as appropriate, except for smoking status, 589 
parity and Caesarean sections and early-onset PE, which are shown as number (percentage). 590 
NC: normotensive control; PE: pre-eclampsia; BMI: body mass index. †P<0.05 between 591 
normotensive controls and women with pre-eclampsia. 592 I r vi
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